Posted by Michael Wonder on 03 Jul 2023
Cyltezo, first and only FDA approved interchangeable biosimilar to Humira, now commercially available in the US
1 July 2023 - Cyltezo is the only adalimumab biosimilar with Phase 3 comparative clinical studies in rheumatoid arthritis, plaque psoriasis and Crohn's disease.
Boehringer Ingelheim announced today that Cyltezo (adalimumab-adbm), a US FDA approved Interchangeable biosimilar to Humira (adalimumab), is now commercially available in the US.
